company background image
6C1 logo

CytomX Therapeutics DB:6C1 Stock Report

Last Price

€1.03

Market Cap

€81.8m

7D

-5.1%

1Y

-18.8%

Updated

23 Dec, 2024

Data

Company Financials +

6C1 Stock Overview

An oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. More details

6C1 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

CytomX Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for CytomX Therapeutics
Historical stock prices
Current Share PriceUS$1.03
52 Week HighUS$4.40
52 Week LowUS$0.78
Beta1.03
1 Month Change21.22%
3 Month Change3.76%
1 Year Change-18.84%
3 Year Change-71.59%
5 Year Change-86.29%
Change since IPO-88.92%

Recent News & Updates

Recent updates

Shareholder Returns

6C1DE BiotechsDE Market
7D-5.1%-3.5%-2.0%
1Y-18.8%-14.7%6.9%

Return vs Industry: 6C1 underperformed the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: 6C1 underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is 6C1's price volatile compared to industry and market?
6C1 volatility
6C1 Average Weekly Movement12.8%
Biotechs Industry Average Movement6.8%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 6C1's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 6C1's weekly volatility has decreased from 27% to 13% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2008121Sean McCarthywww.cytomx.com

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine.

CytomX Therapeutics, Inc. Fundamentals Summary

How do CytomX Therapeutics's earnings and revenue compare to its market cap?
6C1 fundamental statistics
Market cap€81.75m
Earnings (TTM)€13.25m
Revenue (TTM)€121.35m

6.2x

P/E Ratio

0.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6C1 income statement (TTM)
RevenueUS$126.62m
Cost of RevenueUS$0
Gross ProfitUS$126.62m
Other ExpensesUS$112.79m
EarningsUS$13.83m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.18
Gross Margin100.00%
Net Profit Margin10.92%
Debt/Equity Ratio0%

How did 6C1 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:36
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CytomX Therapeutics, Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Etzer DaroutBMO Capital Markets Equity Research
Ying HuangBofA Global Research